{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:14:51Z","timestamp":1788437691374,"version":"build-2803163510"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Antidepressant prescribing in major depressive disorder (MDD) remains dominated by sequential trial and error, particularly when illness becomes difficult to treat (DTD) or meets conventional treatment-resistant depression (TRD) criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This narrative review evaluates pharmacogenomics (PGx), therapeutic drug monitoring (TDM), metabolomics\/lipidomics, immune-inflammatory markers, proteomics, transcriptomics, epigenomics, microbiomics, and multi-omics machine learning according to their capacity to improve defined pharmacological decisions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Evidence was identified through structured PubMed\/MEDLINE searches updated to 29 July 2026, targeted searches of\n                      <jats:ext-link>ClinicalTrials.gov<\/jats:ext-link>\n                      and the WHO International Clinical Trials Registry Platform, and backward and forward citation searching. The review was restricted to adult MDD and used author-assigned categories that distinguish prognostic, predictive, pharmacokinetic, and treatment-emergent monitoring markers and differentiate discovery, independent replication, external validation, and clinical utility. The article is a narrative Review, not a PRISMA systematic review; study selection, extraction, and translational classification were performed by one author without formal study-level risk-of-bias grading.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Most evidence derives from general adult MDD rather than prospectively defined DTD\/TRD cohorts. Drug-specific, guideline-supported PGx and indication-specific TDM are the most clinically proximal molecular tools, but their value is bounded and depends on medication history, inhibitors and inducers, adherence, organ function, assay coverage, and phenoconversion. Commercial combinatorial PGx trials show small and sometimes nonpersistent clinical effects. Metabolomic, inflammatory, proteomic, transcriptomic, epigenomic, microbiomic, and integrated machine-learning studies identify plausible mechanisms and candidate predictors, but the majority remain discovery-stage or internally validated. Positive subgroup signals, including C-reactive protein-defined differential response, are counterbalanced by null prospective trials and inconsistent thresholds.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Current clinical application should remain limited to systematic medication and interaction review, drug-specific guideline-supported PGx, and indication-specific TDM. Dynamic omics layers should be treated as investigational until locked models are externally validated and prospective biomarker-guided strategies demonstrate incremental decision value, clinical benefit, feasibility, equity, and cost-effectiveness. The review proposes a future-state architecture and staged evidence-to-implementation framework for DTD\/TRD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1934360","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:26:36Z","timestamp":1788434796000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmaco-multiomics in major depressive disorder: a narrative review and proposed translational framework for difficult-to-treat and treatment-resistant depression"],"prefix":"10.3389","volume":"17","author":[{"given":"Bernhard T.","family":"Baune","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, University of M\u00fcnster","place":["M\u00fcnster, Germany"]},{"name":"School of Medicine, University of Western Australia","place":["Perth, WA, Australia"]},{"name":"Department of Psychiatry, University of Melbourne","place":["Melbourne, VIC, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.jad.2022.09.011","article-title":"Understanding treatment-resistant depression using omics techniques: a systematic review","volume":"318","author":"Amasi-Hartoonian","year":"2022","journal-title":"J. Affect Disord."},{"key":"B2","doi-asserted-by":"publisher","first-page":"104068","DOI":"10.1016\/j.drudis.2024.104068","article-title":"Machine learning for antidepressant treatment selection in depression","volume":"29","author":"Arnold","year":"2024","journal-title":"Drug Discov. Today"},{"key":"B3","doi-asserted-by":"publisher","first-page":"104966","DOI":"10.1016\/j.neubiorev.2022.104966","article-title":"Pharmacogenomic testing in depression: a systematic review and meta-analysis of randomized controlled trials","volume":"144","author":"Arnone","year":"2023","journal-title":"Neurosci. Biobehav Rev."},{"key":"B4","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1002\/cpt.1482","article-title":"Pharmacogenomics-driven prediction of antidepressant treatment outcomes: a machine-learning approach with multi-trial replication","volume":"106","author":"Athreya","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/s41431-024-01648-1","article-title":"Dutch Pharmacogenetics Working Group guideline for the gene-drug interaction between CYP2D6, CYP2C19 and non-SSRI\/non-TCA antidepressants","volume":"32","author":"Beunk","year":"2024","journal-title":"Eur. J. Hum. Genet."},{"key":"B6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/cpt.2903","article-title":"Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants","volume":"114","author":"Bousman","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/s41431-021-01004-7","article-title":"Dutch Pharmacogenetics Working Group guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs","volume":"30","author":"Brouwer","year":"2022","journal-title":"Eur. J. Hum. Genet."},{"key":"B8","doi-asserted-by":"publisher","first-page":"55","DOI":"10.7326\/M14-0697","article-title":"Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis: the TRIPOD statement","volume":"162","author":"Collins","year":"2015","journal-title":"Ann. Intern Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e23009","DOI":"10.7759\/cureus.23009","article-title":"Metabolomics of major depressive disorder: a systematic review of clinical studies","volume":"14","author":"Costa","year":"2022","journal-title":"Cureus"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e32985","DOI":"10.1002\/ajmg.b.32985","article-title":"Leveraging DNA methylation to predict treatment response in major depressive disorder: a critical review","volume":"195","author":"Dahrendorff","year":"2024","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.3390\/ijms26031082","article-title":"Pharmaco-multiomics: a new frontier in precision psychiatry","volume":"26","author":"Dhieb","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1038\/s41380-024-02857-2","article-title":"Medication use is associated with distinct microbial features in anxiety and depression","volume":"30","author":"Dilmore","year":"2025","journal-title":"Mol. Psychiatry"},{"key":"B13","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/FPC.0000000000000525","article-title":"Prevalence of CYP2D6 structural variation in large retrospective study","volume":"34","author":"Frear","year":"2024","journal-title":"Pharmacogenet Genomics."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e0285123","DOI":"10.1371\/journal.pone.0285123","article-title":"Multi-omic modeling of antidepressant response implicates dynamic immune and inflammatory changes in individuals who respond to treatment","volume":"18","author":"Fuh","year":"2023","journal-title":"PLoS One"},{"key":"B15","doi-asserted-by":"publisher","first-page":"36","DOI":"10.64719\/pb.4425","article-title":"Inflammatory biomarker and response to antidepressant in major depressive disorder: a systematic review and meta-analysis","volume":"52","author":"Gasparini","year":"2022","journal-title":"Psychopharmacol. Bull."},{"key":"B16","doi-asserted-by":"publisher","first-page":"984383","DOI":"10.3389\/fphar.2022.984383","article-title":"Network science approach elucidates integrative genomic-metabolomic signature of antidepressant response and lifetime history of attempted suicide in adults with major depressive disorder","volume":"13","author":"Grant","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jpsychires.2019.01.003","article-title":"Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial","volume":"111","author":"Greden","year":"2019","journal-title":"J. Psychiatr. Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e2230367","DOI":"10.1001\/jamanetworkopen.2022.30367","article-title":"Effect of minocycline on depressive symptoms in patients with treatment-resistant depression: a randomized clinical trial","volume":"5","author":"Hellmann-Regen","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e89352","DOI":"10.2196\/89352","article-title":"Machine learning for comparative antidepressant selection in major depressive disorder: systematic review","volume":"13","author":"He","year":"2026","journal-title":"JMIR Ment. Health"},{"key":"B20","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41522-025-00707-9","article-title":"Multi-omics approach identifies gut microbiota variations associated with depression","volume":"11","author":"Hernandez-Cacho","year":"2025","journal-title":"NPJ Biofilms Microbiomes"},{"key":"B21","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/cpt.597","article-title":"Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update","volume":"102","author":"Hicks","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"B23","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/JCP.0000000000001387","article-title":"Dose-dependent inhibition of CYP2D6 by bupropion in patients with depression","volume":"41","author":"Hole","year":"2021","journal-title":"J. Clin. Psychopharmacol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3722","DOI":"10.1038\/s41380-024-02613-6","article-title":"The metabolome-wide signature of major depressive disorder","volume":"29","author":"Jansen","year":"2024","journal-title":"Mol. Psychiatry"},{"key":"B25","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.psyneuen.2017.01.023","article-title":"Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial","volume":"78","author":"Jha","year":"2017","journal-title":"Psychoneuroendocrinology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41398-024-03208-z","article-title":"The role of gut microbiota and metabolomic pathways in modulating the efficacy of SSRIs for major depressive disorder","volume":"14","author":"Jiang","year":"2024","journal-title":"Transl. Psychiatry"},{"key":"B27","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/s41398-021-01632-z","article-title":"Multi-omics driven predictions of response to acute phase combination antidepressant therapy: a machine learning approach with cross-trial replication","volume":"11","author":"Joyce","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"B28","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41398-019-0589-0","article-title":"Integrated genome-wide methylation and expression analyses reveal functional predictors of response to antidepressants","volume":"9","author":"Ju","year":"2019","journal-title":"Transl. Psychiatry"},{"key":"B29","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s12888-026-07893-6","article-title":"Peripheral blood transcriptomic biomarkers for predicting antidepressant response in major depressive disorder","volume":"26","author":"Kang","year":"2026","journal-title":"BMC Psychiatry"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.3390\/jcm9092890","article-title":"Phenoconversion of cytochrome P450 metabolism: a systematic review","volume":"9","author":"Klomp","year":"2020","journal-title":"J. Clin. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1080\/17520363.2026.2641467","article-title":"Identifying predictive proteomic biomarkers of selective serotonin reuptake inhibitor treatment effect in depression","volume":"20","author":"Lee","year":"2026","journal-title":"Biomark. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/s41380-019-0474-5","article-title":"Peripheral cytokine levels and response to antidepressant treatment in depression: a systematic review and meta-analysis","volume":"25","author":"Liu","year":"2020","journal-title":"Mol. Psychiatry"},{"key":"B33","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41398-020-01097-6","article-title":"Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram\/escitalopram in major depression","volume":"11","author":"MahmoudianDehkordi","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"B34","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jad.2020.02.023","article-title":"The identification, assessment and management of difficult-to-treat depression: a review of current literature and a consensus statement","volume":"267","author":"McAllister-Williams","year":"2020","journal-title":"J. Affect Disord."},{"key":"B35","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/s41386-020-00948-6","article-title":"Augmentation therapy with minocycline in treatment-resistant depression patients with low-grade peripheral inflammation: results from a double-blind randomised clinical trial","volume":"46","author":"Nettis","year":"2021","journal-title":"Neuropsychopharmacology"},{"key":"B36","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.euroneuro.2025.05.004","article-title":"Predicted plasma proteomics from genetic scores and treatment outcomes in major depression: a meta-analysis","volume":"96","author":"Oliva","year":"2025","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1001\/jama.2022.9805","article-title":"Effect of pharmacogenomic testing for drug-gene interactions on medication selection and remission of symptoms in major depressive disorder: the PRIME Care randomized clinical trial","volume":"328","author":"Oslin","year":"2022","journal-title":"JAMA"},{"key":"B38","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B39","doi-asserted-by":"publisher","first-page":"867840","DOI":"10.3389\/fpsyt.2022.867840","article-title":"Therapeutic drug monitoring of antidepressants: an underused but potentially valuable tool in primary care","volume":"13","author":"Piacentino","year":"2022","journal-title":"Front. Psychiatry"},{"key":"B40","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1001\/2013","article-title":"A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers","volume":"70","author":"Raison","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"B41","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13643-020-01542-z","article-title":"PRISMA-S: an extension to the PRISMA statement for reporting literature searches in systematic reviews","volume":"10","author":"Rethlefsen","year":"2021","journal-title":"Syst. Rev."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"B43","doi-asserted-by":"publisher","first-page":"pyae045","DOI":"10.1093\/ijnp\/pyae045","article-title":"Epigenome-wide DNA methylation in unipolar depression: predictive biomarker of antidepressant treatment response?","volume":"27","author":"Schiele","year":"2024","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1038\/s41380-024-02736-w","article-title":"Transcriptomic profiles in major depressive disorder: the role of immunometabolic and cell-cycle-related pathways in depression with different levels of inflammation","volume":"30","author":"Sforzini","year":"2025","journal-title":"Mol. Psychiatry"},{"key":"B45","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/s41398-024-02998-6","article-title":"Pharmacogenomic scores in psychiatry: systematic review of current evidence","volume":"14","author":"Sharew","year":"2024","journal-title":"Transl. Psychiatry"},{"key":"B46","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool to assess risk of bias in randomized trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1276410","DOI":"10.3389\/fpsyt.2024.1276410","article-title":"Efficacy and safety of pharmacogenomic-guided antidepressant prescribing in patients with depression: an umbrella review and updated meta-analysis","volume":"15","author":"Tesfamicael","year":"2024","journal-title":"Front. Psychiatry"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1176\/appi.ajp.2014.14010094","article-title":"An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline","volume":"171","author":"Uher","year":"2014","journal-title":"Am. J. Psychiatry"},{"key":"B49","doi-asserted-by":"publisher","first-page":"51","DOI":"10.7326\/M18-1376","article-title":"PROBAST: a tool to assess the risk of bias and applicability of prediction model studies","volume":"170","author":"Wolff","year":"2019","journal-title":"Ann. Intern Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1429116","DOI":"10.3389\/fmicb.2024.1429116","article-title":"Baseline gut microbiota profiles affect treatment response in patients with depression","volume":"15","author":"Xie","year":"2024","journal-title":"Front. Microbiol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1186\/s12982-025-00816-y","article-title":"Evaluating the impact of machine learning models on adult major depressive disorder using conventional treatment strategies: a systematic review approach","volume":"22","author":"Yadav","year":"2025","journal-title":"Discov. Public Health"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1934360\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:26:37Z","timestamp":1788434797000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1934360\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":51,"alternative-id":["10.3389\/fphar.2026.1934360"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1934360","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"1934360"}}